Nektar Therapeutics

NKTRNASDAQHealthcare● Active

$56.07

$-1.25(-2.18%)

Market Cap$1.1B

P/E Ratio—

52W High$109

52W Low$7.99

Avg Volume1.0M

Open$57.20

Beta1.15

Insider Trades Ownership Employees

Nektar Therapeutics (NKTR) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · NKTR · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Nektar Therapeutics insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

NKTR insider buying and selling by quarter

NKTR insider selling · NKTR insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

4.1M2.1M0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · NKTR ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

NKTR executive sell shares · NKTR board member insider trading · NKTR insider trading SEC filing

Showing 66 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 19, 2026	Zalevsky Jonathan Chief R&D Officer	Sale	199	$65.51	$13K	20,975	Form 4
May 19, 2026	ROBIN HOWARD W President & CEO · Director	Sale	444	$65.51	$29K	75,045	Form 4
Feb 18, 2026	Zalevsky Jonathan Chief R&D Officer	Sale	180	$73.00	$13K	21,174	Form 4
Feb 18, 2026	ROBIN HOWARD W President & CEO · Director	Sale	423	$73.00	$31K	75,489	Form 4
Jan 20, 2026	Zalevsky Jonathan Chief R&D Officer	Sale	3,867	$35.67	$138K	21,354	Form 4
Dec 22, 2025	Zalevsky Jonathan Chief R&D Officer	Award	6,250	—	—	25,221	Form 4
Dec 22, 2025	ROBIN HOWARD W President & CEO · Director	Award	21,667	—	—	75,912	Form 4
Nov 21, 2025	Zalevsky Jonathan Chief R&D Officer	Award	2,666	—	—	20,128	Form 4
Nov 25, 2025	Zalevsky Jonathan Chief R&D Officer	Sale	1,157	$54.28	$63K	18,971	Form 4
Nov 21, 2025	Wilson Mark Andrew Chief Legal Officer	Award	1,903	—	—	22,215	Form 4
Nov 25, 2025	Wilson Mark Andrew Chief Legal Officer	Sale	630	$54.28	$34K	21,585	Form 4
Nov 21, 2025	ROBIN HOWARD W President & CEO · Director	Award	7,110	—	—	56,452	Form 4
Nov 25, 2025	ROBIN HOWARD W President & CEO · Director	Sale	2,207	$54.28	$120K	54,245	Form 4
Sep 9, 2025	ROBIN HOWARD W President & CEO · Director	Sale	2,100	$45.16	$95K	53,908	Form 4
Sep 9, 2025	ROBIN HOWARD W President & CEO · Director	Sale	1,200	$46.41	$56K	52,708	Form 4
Sep 9, 2025	ROBIN HOWARD W President & CEO · Director	Sale	2,156	$47.49	$102K	50,552	Form 4
Sep 9, 2025	ROBIN HOWARD W President & CEO · Director	Sale	1,210	$48.18	$58K	49,342	Form 4
Sep 4, 2025	Zalevsky Jonathan Chief R&D Officer	Sale	793	$32.43	$26K	18,390	Form 4
Sep 4, 2025	Zalevsky Jonathan Chief R&D Officer	Sale	432	$33.60	$15K	17,958	Form 4
Sep 4, 2025	Zalevsky Jonathan Chief R&D Officer	Sale	189	$34.41	$7K	17,769	Form 4
Sep 4, 2025	Zalevsky Jonathan Chief R&D Officer	Sale	307	$35.69	$11K	17,462	Form 4
Sep 4, 2025	ROBIN HOWARD W President & CEO · Director	Sale	1,923	$32.37	$62K	65,917	Form 4
Sep 4, 2025	ROBIN HOWARD W President & CEO · Director	Sale	1,496	$33.54	$50K	64,421	Form 4
Sep 4, 2025	ROBIN HOWARD W President & CEO · Director	Sale	613	$34.40	$21K	63,808	Form 4
Sep 4, 2025	ROBIN HOWARD W President & CEO · Director	Sale	1,134	$35.80	$41K	62,674	Form 4

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

May 19

199

Price

$65.51

Value

$13K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

May 19

444

Price

$65.51

Value

$29K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Feb 18

180

Price

$73.00

Value

$13K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Feb 18

423

Price

$73.00

Value

$31K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Jan 20

3,867

Price

$35.67

Value

$138K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Award

Date

Dec 22

6,250

Price

—

Value

—

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Award

Date

Dec 22

21,667

Price

—

Value

—

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Award

Date

Nov 21

2,666

Price

—

Value

—

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Nov 25

1,157

Price

$54.28

Value

$63K

View Form 4 on SEC.gov

Wilson Mark Andrew

Chief Legal Officer

Award

Date

Nov 21

1,903

Price

—

Value

—

View Form 4 on SEC.gov

Wilson Mark Andrew

Chief Legal Officer

Sale

Date

Nov 25

630

Price

$54.28

Value

$34K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Award

Date

Nov 21

7,110

Price

—

Value

—

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Nov 25

2,207

Price

$54.28

Value

$120K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 9

2,100

Price

$45.16

Value

$95K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 9

1,200

Price

$46.41

Value

$56K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 9

2,156

Price

$47.49

Value

$102K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 9

1,210

Price

$48.18

Value

$58K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Sep 4

793

Price

$32.43

Value

$26K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Sep 4

432

Price

$33.60

Value

$15K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Sep 4

189

Price

$34.41

Value

$7K

View Form 4 on SEC.gov

Zalevsky Jonathan

Chief R&D Officer

Sale

Date

Sep 4

307

Price

$35.69

Value

$11K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 4

1,923

Price

$32.37

Value

$62K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 4

1,496

Price

$33.54

Value

$50K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 4

613

Price

$34.40

Value

$21K

View Form 4 on SEC.gov

ROBIN HOWARD W

President & CEO · Director

Sale

Date

Sep 4

1,134

Price

$35.80

Value

$41K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About NKTR insider trading

NKTR insider trades

Nektar Therapeutics (NKTR) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including ROBIN HOWARD W (President & CEO · Director), Zalevsky Jonathan (Chief R&D Officer), Wilson Mark Andrew (Chief Legal Officer). Over the past 12 months, 3 insiders have filed transactions with the SEC. NKTR insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Nektar Therapeutics's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

NKTR insider trading · 5 questions

The insiders of Nektar Therapeutics (NKTR) include executives and directors such as ROBIN HOWARD W (President & CEO · Director), Zalevsky Jonathan (Chief R&D Officer), Wilson Mark Andrew (Chief Legal Officer), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

NKTR board member insider tradingwho are NKTR insidersNKTR insider rosterNektar Therapeutics executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026